Business
MIRA Pharmaceuticals to Host Virtual Roadshow Webinar on Monday, September 11, 2023 at 1:00 p.m. Eastern Time
BALTIMORE, Aug. 29, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company
About this update from Mira Pharmaceuticals, Inc.
[{"type":"text","content":"BALTIMORE, Aug. 29, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) (\"MIRA\" or the \"Company\"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of a novel synthetic THC analog, will host a virtual roadshow webinar on Monday, September 11, 2023 at 1:00 p.m. Eastern Time.\nErez Aminov, Chief Executive Officer of MIRA Pharmaceuticals, will present an overview of the Company's growth strategy and operational roadmap. The webinar will be accompanied by a presentation and followed by a question-and-answer session, which can be accessed via the webcast link or dial-in numbers below.\nTo access the webinar, please use the following information:\nDate: \nMonday, September 11, 2023\nTime: \n1:00 p.m. Eastern Time\nDial-in (U.S.): \n1-877-269-7751\nInternational Dial-in: \n1-201-389-0908\nWebcast: \nMIRA Virtual Roadshow\nA telephone replay will be available approximately three hours after the call and will run through Monday, October 9, 2023, by dialing 1-844-512-2921 from the U.S., or 1-412-317-6671 from international locations, and entering replay pin number: 13740748. The replay can also be viewed through the webinar webcast link above.\nAbout MIRA Pharmaceuticals, Inc.\nMIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) is a pre-clinical-stage pharmaceutical development company developing an unscheduled novel synthetic THC analog. This novel compound is currently under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. MIRA1a, if approved by the FDA, could mark a significant advancement in addressing various neuropsychiatric, inflammatory, and neurologic diseases and disorders. Based on pre-clinical and animal studies conducted by the Company, the Company believes that MIRA1a may enhance the therapeutic potential for treating anxiety, cognitive decline, and neuropathic pain without the side effects of plant-based THC. Furthermore, the Company's studies indicate that MIRA1a may counteract the adverse cognitive effects often seen with THC, thereby potentially unmasking previously unseen positive therapeutic effects, such as cognitive performance enhancement.\nThe U.S. Drug Enforcement Administration (DEA)'s scientific review of MIRA1a concluded that MIRA1a would not be considered a controlled substance o...